- Home
- CULP vs CGTX Comparison
CULP vs CGTX Comparison
Compare CULP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CULP | CGTX |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.7M | 158.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CULP | CGTX |
|---|---|---|
| Price | $3.85 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.88 |
| AVG Volume (30 Days) | 21.1K | ★ 938.3K |
| Earning Date | 12-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $207,391,000.00 | N/A |
| Revenue This Year | $1.93 | N/A |
| Revenue Next Year | $2.77 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.42 | $0.22 |
| 52 Week High | $5.94 | $3.83 |
Technical Indicators
Market Signals| Indicator | CULP | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 53.42 |
| Support Level | $3.78 | $1.69 |
| Resistance Level | $3.94 | $1.77 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 7.69 | 80.34 |
Price Performance
Historical ComparisonAbout CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.